Bills › HF 2201 › What changed
What changed in HF 2201
The bill as introduced, compared with the version both chambers passed (89th General Assembly).
It passed exactly as introduced.
Removed AddedIntroduced textText as passedAmendments
DIVISION I CONTROLLED SUBSTANCE SCHEDULES —— PRECURSOR SUBSTANCES REPORTING
99 unchanged passages
Section 1. Section 124.204, subsection 2, Code 2022, is amended by adding the following new paragraphs:
NEW PARAGRAPH.
bt. N-phenyl-N-(1-(2-phenylpropyl) piperidin-4-yl)propionamide. Other name: beta-methyl fentanyl.
NEW PARAGRAPH.
bu. N-(1-phenethylpiperidin-4yl) -N,3-diphenylpropanamide. Other names: beta’-Phenyl fentanyl, 3-phenylpropanoyl fentanyl.
NEW PARAGRAPH.
bv. N-(1-(2-flourophenethyl)piperidin-4-yl) -N-(2-fluorophenyl)propionamide. Other names: 2’-Fluoro ortho-fluorofentanyl, 2’-fluoro 2-fluorofentanyl.
NEW PARAGRAPH.
bw. N-(1-(4-methylphenethyl)piperidin-4-yl) -N-phenylacetamide. Other name: 4’-Methyl acetyl fentanyl.
NEW PARAGRAPH.
bx. N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)butyramide. Other names: ortho-Fluorobutyryl fentanyl, 2-fluorobutyryl fentanyl.
NEW PARAGRAPH.
by. N-(2-methylphenyl)-N-(1- phenethylpiperidin-4-yl)acetamide. Other names: ortho-Methyl acetylfentanyl, 2-methyl acetylfentanyl.
NEW PARAGRAPH.
bz. 2-methoxy-N-(2-methylphenyl)-N- (1-phenethylpiperidin-4-yl)acetamide. Other names: ortho-Methyl methoxyacetyl fentanyl, 2-methyl methoxyacetyl fentanyl.
NEW PARAGRAPH.
ca. N-(4-methylphenyl)-N-(1- phenethylpiperidin-4-yl)propionamide. Other names: para-Methylfentanyl, 4-methylfentanyl.
NEW PARAGRAPH.
cb. N-(1-phenethylpiperidin-4-yl) -N-phenylbenzamide. Other names: Phenyl fentanyl, benzoyl fentanyl.
NEW PARAGRAPH.
cc. N-(1-phenethylpiperidin-4-yl) -N-phenylthiophene-2-carboxamide. Other names: Thiofuranyl fentanyl, 2-thiofuranyl fentanyl, thiophene fentanyl.
NEW PARAGRAPH.
cd. Ethyl (1-phenethylpiperidin- 4-yl)(phenyl)carbamate. Other name: fentanyl carbamate.
NEW PARAGRAPH.
ce. N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide. Other name: ortho-Fluoroacryl fentanyl.
NEW PARAGRAPH.
cf. N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide. Other name: ortho-Fluoroisobutyryl fentanyl.
NEW PARAGRAPH.
cg. N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2-carboxamide. Other name: para-Fluoro furanyl fentanyl.
NEW PARAGRAPH.
ch. N-(1-phenethylpiperidin-4-yl)-N- phenylpentanamide. Other name: valeryl fentanyl.
NEW PARAGRAPH.
ci. N-(4-methyoxyphenyl)-N-(1- phenethylpiperidin-4-yl)butyramide. Other name: para-methyoxybutyryl fentanyl.
NEW PARAGRAPH.
cj. N-(4-chlorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide. Other name: para-Chloroisobutyryl fentanyl.
NEW PARAGRAPH.
ck. N-(1-phenethylpiperidin-4-yl) -N-phenylisobutryamide. Other name: Isobutyryl fentanyl.
NEW PARAGRAPH.
cl. N-(1-phenethylpiperidin-4-yl) -N-phenylcyclopentanecarboxamide. Other name: cyclopentanyl fentanyl.
NEW PARAGRAPH.
cm. N,N-diethyl-2-(2-(4-isopropoxybenzyl) -5-nitro-1H-benzimidazol-1-yl)ethan-1-amine. Other name: isotonitazene.
Sec.
2. Section 124.204, subsection 4, Code 2022, is amended by adding the following new paragraphs:
NEW PARAGRAPH.
bs. methyl 2-(1-(4-fluorobutyl)- 1H-indazole-3-carboxamido)-3,3-dimethylbutanoate. Other names: 4F-MDMB-BINACA, 4F-MDMB-BUTINACA.
NEW PARAGRAPH.
bt. 1-(4-methyoxyphenyl)-N- methylpropan-2-amine. Other names: para-methoxymethamphetamine, PMMA.
NEW PARAGRAPH.
bu. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate. Other names: NM2201 or CBL2201.
NEW PARAGRAPH.
bv. N-(1-amino-3-methyl-1-oxobutan-2-yl) -1-(5-fluoropentyl)-1H-indazole-3-carboxamide. Other name: 5F-AB-PINACA.
NEW PARAGRAPH.
bw. 1-(4-cyanobutyl)-N-(2-phenylpropan -2-yl)-1H-indazole-3-carboxamide. Other names: 4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA, 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, or SGT-78.
NEW PARAGRAPH.
bx. Methyl 2-(1-(cyclohexylmethyl)- 1H-indole-3-carboxamido)-3-methylbutanoate. Other names: MMB-CHMICA or AMB-CHMICA.
NEW PARAGRAPH.
by. 1-(5-fluoropentyl)-N-(2-phenylpropan -2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide. Other name: 5F-CUMYL-P7AICA.
NEW PARAGRAPH.
bz. 1-(1,3-benzodioxol-5-yl)-2- (ethylamino)-pentan-1-one. Other names: N-ethylpentylone or ephylone.
Sec.
3. Section 124.204, subsection 6, Code 2022, is amended by adding the following new paragraph:
NEW PARAGRAPH.
i. 4,4’-Dimethylaminorex. Other names: 4,4’-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)- 2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3- oxazol-2-amine.
Sec.
4. Section 124.204, subsection 7, paragraph b, Code 2022, is amended to read as follows:
b. A hemp product as provided in chapter 204 with a maximum tetrahydrocannabinol concentration, inclusive of any isomers, derivatives, and analogs, whether naturally occurring or synthesized, that does not exceed three-tenths of one percent on a dry weight basis.
Sec.
5. Section 124.204, subsection 9, paragraphs a, h, i, j, k, l, n, o, p, q, and r, Code 2022, are amended by striking the paragraphs.
Sec.
6. Section 124.204, subsection 9, paragraph x, Code 2022, is amended by striking the paragraph and inserting in lieu thereof the following:
x. 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1, 3-dihydro-2H-benzo[d]imidazole-2-one. Other names: brorphine, 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1, 3-dihydro-2H-benzimidazol-2-one.
Sec.
7. Section 124.206, subsection 2, paragraph a, Code 2022, is amended by striking the paragraph and inserting in lieu thereof the following:
a. Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6beta-naltrexol, naltrexone, and samidorphan, and their respective salts, but including the following:
Sec.
8. Section 124.210, subsection 6, Code 2022, is amended by adding the following new paragraph:
NEW PARAGRAPH.
n. Serdexmethylphenidate.
Sec.
9. Section 124.212, subsection 5, Code 2022, is amended by adding the following new paragraph:
NEW PARAGRAPH.
f. Lasmiditan [2,4,6-trifluoro-N-(6- (1-methylpiperine-4-carbonyl)pyridine-2-yl-benzamide].
Sec.
10. Section 124B.2, subsection 1, Code 2022, is amended by adding the following new paragraphs:
NEW PARAGRAPH.
ae. 3,4-MDP-2-P methyl glycidate (PMK glycidate) and its optical and geometric isomers.
NEW PARAGRAPH.
af. 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its salts, optical and geometric isomers, and salts of isomers.
NEW PARAGRAPH.
ag. Alpha-phenylacetoacetamide (APAA) and its optical isomers.
Sec.
11. EFFECTIVE DATE. This division of this Act, being deemed of immediate importance, takes effect upon enactment. DIVISION II IOWA PRESCRIPTION MONITORING PROGRAM
Sec.
12. Section 124.555, unnumbered paragraph 1, Code 2022, is amended to read as follows: An advisory council shall be established to provide oversight to the board and the program and to comanage program activities. The board and advisory council shall jointly adopt rules specifying the duties and activities of the advisory council and related matters.
Sec.
13. Section 124.555, subsection 1, Code 2022, is amended to read as follows:
1. The council shall consist of eight members appointed by the governor board. The members shall include three at least one licensed pharmacists pharmacist, four physicians one physician licensed under chapter 148, and one licensed prescribing practitioner who is not a physician, and other members as determined by the board. The board shall adopt rules in accordance with chapter 17A on matters pertaining to the council membership, including the terms of appointment and quorum. The governor board shall solicit recommendations for council members from Iowa health professional licensing boards, associations, and societies. The license of each member appointed to and serving on the advisory council shall be current and in good standing with the professional’s licensing board.
Sec.
14. Section 124.555, subsection 3, paragraph e, Code 2022, is amended to read as follows:
e. One physician and one pharmacist member of the council shall include in their duties the responsibility for monitoring Monitoring and ensuring that patient confidentiality, best interests, and civil liberties are at all times protected and preserved during the existence of the program.